<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02671695</url>
  </required_header>
  <id_info>
    <org_study_id>22/03/15</org_study_id>
    <nct_id>NCT02671695</nct_id>
  </id_info>
  <brief_title>Effect of Spirulina Compared to Amlodipine on Cardiac Iron Overload in Children With Beta Thalassemia</brief_title>
  <official_title>Effect of Spirulina Compared to Amlodipine on Cardiac Iron Overload in Children With Beta Thalassemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      the aim of this study is to evaluate the effect of Spirulina compared to Amlodipine on
      cardiac iron overload and cardiac functions in multi-transfused children with beta
      thalassemia major
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      the aim of this study is to evaluate the effect of Spirulina compared to Amlodipine on
      cardiac iron overload using magnetic resonance imaging and cardiac functions in
      multi-transfused children with beta thalassemia major
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cardiac iron concentration by magnetic resonance imaging</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>cardiac troponin 1</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-terminal pro-brain natriuretic peptide</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Beta Thalassemia Major</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>chelation therapy plus Spirulina capsules (500 mg) in a dose of 250 mg/kg/day orally for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>chelation therapy plus Amlodipine in a dose of 5 mg/day orally for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spirulina</intervention_name>
    <description>Spirulina capsules (500 mg) in a dose of 250 mg/kg/day orally for 3 months</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>Amlodipine in a dose of 5 mg/day orally for 3 months</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients on regular blood transfusions.

          -  iron overload with no perspective of changing the chelation therapy in the following
             three months

        Exclusion Criteria:

          -  formal contraindication to magnetic resonance examinations

          -  implantable cardiac device

          -  advanced cardiomyopathy or conduction block

          -  other types of hemolytic anemias
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sahar M El-Haggar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>assisstant professor of clinical pharmacy- Faculty of Pharmacy- Tanta University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine- Tanta University</name>
      <address>
        <city>Tanta</city>
        <state>Gharbia</state>
        <zip>0000</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2016</study_first_submitted>
  <study_first_submitted_qc>January 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2016</study_first_posted>
  <last_update_submitted>October 14, 2017</last_update_submitted>
  <last_update_submitted_qc>October 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Professor Mohamed Elshanshory</investigator_full_name>
    <investigator_title>head of pediatric hematology and oncology unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>Iron Overload</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

